Goldman Sachs’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Goldman Sachs’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-114,476	Closed	-$11.2M	–	7642
2015 Q1	$11.2M	Buy	114,476 +1,197	+1%	+$127K	﹤0.01%	2210
2014 Q4	$10.5M	Sell	113,279 -9,839	-8%	-$776K	﹤0.01%	2306
2014 Q3	$8.47M	Sell	123,118 -982	-0.8%	-$70.3K	﹤0.01%	2498
2014 Q2	$13M	Sell	124,100 -10,594	-8%	-$901K	﹤0.01%	2152
2014 Q1	$11.2M	Sell	134,694 -16,713	-11%	-$1.55M	﹤0.01%	2280
2013 Q4	$9.8M	Buy	151,407 +11,445	+8%	+$679K	﹤0.01%	2385
2013 Q3	$8.87M	Buy	139,962 +16,097	+13%	+$792K	﹤0.01%	2368
2013 Q2	$5.2M	Buy	+123,865	New	+$5.64M	﹤0.01%	2694

Goldman Sachs's GEVA Position: Q2 2015 in Review

Goldman Sachs sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 114,476 shares — an estimated $11.2M sold.

Goldman Sachs first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $13M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Goldman Sachs reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Goldman Sachs sold 114,476 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $11.2M.
Goldman Sachs first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
Goldman Sachs's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $13M in Q2 2014.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Goldman Sachs's 13F filing for Q2 2015, filed 14 Aug 2015.